Literature DB >> 22488275

Tumor microenvironment and lymphocyte infiltration.

Gwendoline Rahir1, Muriel Moser.   

Abstract

There is ample evidence that the presence of tumor-infiltrating T lymphocytes is associated with a favorable prognostic in patients. These observations suggest that a limiting step to immune resistance and immunotherapy could be the capacity of tumor-specific T cells to reach tumor bed. In this article, we review some factors that may influence this infiltration, and in particular the nature of the vasculature, the expression of chemokines or tumor antigens and the presence of dendritic cells and CD4+ T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488275     DOI: 10.1007/s00262-012-1253-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  35 in total

1.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

2.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

Review 3.  Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.

Authors:  Alexander G Raufi; Samuel J Klempner
Journal:  J Gastrointest Oncol       Date:  2015-10

4.  Matrix stiffness and tumor-associated macrophages modulate epithelial to mesenchymal transition of human adenocarcinoma cells.

Authors:  Marta Alonso-Nocelo; Theresa M Raimondo; Kyle H Vining; Rafael López-López; Maria de la Fuente; David J Mooney
Journal:  Biofabrication       Date:  2018-03-28       Impact factor: 9.954

5.  Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer.

Authors:  Li Xiao; Ulrike Erb; Kun Zhao; Thilo Hackert; Margot Zöller
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

Review 6.  Immune checkpoint inhibitors in gastrointestinal malignancies.

Authors:  Vishal Jindal
Journal:  J Gastrointest Oncol       Date:  2018-04

7.  Autophagy inhibition upregulates CD4+ tumor infiltrating lymphocyte expression via miR-155 regulation and TRAIL activation.

Authors:  Paul Zarogoulidis; Savvas Petanidis; Kalliopi Domvri; Efrosini Kioseoglou; Doxakis Anestakis; Lutz Freitag; Konstantinos Zarogoulidis; Wolfgang Hohenforst-Schmidt; Wilfried Eberhardt
Journal:  Mol Oncol       Date:  2016-09-16       Impact factor: 6.603

8.  The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells.

Authors:  Kutlu G Elpek; Viviana Cremasco; Hua Shen; Christopher J Harvey; Kai W Wucherpfennig; Daniel R Goldstein; Paul A Monach; Shannon J Turley
Journal:  Cancer Immunol Res       Date:  2014-03-31       Impact factor: 11.151

9.  Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors.

Authors:  David R Shook; Brandon M Triplett; Ashok Srinivasan; Christine Hartford; Mari H Dallas; Asha Pillai; Joseph Laver; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-09       Impact factor: 5.742

10.  CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.

Authors:  Chunyan Gu-Trantien; Sherene Loi; Soizic Garaud; Carole Equeter; Myriam Libin; Alexandre de Wind; Marie Ravoet; Hélène Le Buanec; Catherine Sibille; Germain Manfouo-Foutsop; Isabelle Veys; Benjamin Haibe-Kains; Sandeep K Singhal; Stefan Michiels; Françoise Rothé; Roberto Salgado; Hugues Duvillier; Michail Ignatiadis; Christine Desmedt; Dominique Bron; Denis Larsimont; Martine Piccart; Christos Sotiriou; Karen Willard-Gallo
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.